Immatics, a Germany-based cancer immunotherapy spinout from University of Tübingen, secured $58m in a series E round yesterday that featured pharmaceutical firm Amgen. Life sciences investment firm Dievini Hopp Biotech, venture capital firm Wellington Partners, AT Impf and unnamed existing investors also participated in the round. Founded in 2000, Immatics has created an antigen discovery…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.